Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3867070 · 1 trial · 1 indication
A summary of TEAEs regardless of causality, will be reported in the Reported Adverse Events module
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
A summary of AEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3867070 (Part A) | EXPERIMENTAL | Single-Ascending Dose of LY3867070 administered orally |
| LY3867070 (Part B) | EXPERIMENTAL | Multiple-Ascending Doses of LY3867070 administered orally |
| LY3867070 (Part C) | EXPERIMENTAL | Multiple Doses of LY3867070 administered orally |
| Placebo (Parts A-C) | PLACEBO_COMPARATOR | Placebo administered orally |
| LY3867070 (Part D) | EXPERIMENTAL | Drug-Drug Interaction (DDI) administered orally |
| Name | Type | Description |
|---|---|---|
| LY3867070 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation * Part C of the study includes only Japanese and Chinese participants * Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive Exclusion...
LY3867070 is an investigational small molecule developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, with study activity in the United States. The specific therapeutic indication for LY3867070 has not been disclosed, and the compound remains under early-stage clinical evaluation.
LY3867070 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the clinical program evaluating this small molecule. The asset is an early-stage investigational compound within the company's pipeline.
LY3867070 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA. The program currently has one active trial, which is no longer recruiting participants. Phase 1 studies primarily evaluate safety, tolerability, and pharmacokinetics in human volunteers.
LY3867070 is being studied in the Phase 1 trial NCT07021547, titled A Study of LY3867070 in Healthy Participants. The trial is active but not recruiting, enrolled 196 participants, and is a randomized, double-blind, placebo-controlled study conducted in the United States with healthy volunteers aged 18 years and older.
Yes. The Phase 1 trial of LY3867070, NCT07021547, is being conducted in healthy participants rather than in patients with a specific disease. The study enrolled 196 adults aged 18 years and older of all sexes, and it uses a randomized, double-blind, placebo-controlled design.